Law360, New York (March 17, 2010, 2:45 PM ET) -- Mylan Inc. has resolved two patent infringement suits brought by Takeda Pharmaceutical Co. Ltd. over plans to market generic versions of diabetes drugs Actos and Actoplus Met.
Mylan said in a statement Tuesday that it had reached settlements with Takeda, bringing a close to litigation in the U.S. District Court for the Southern District of New York. A representative for Takeda confirmed the deals, but declined to comment further.
According to the defendant, the settlements allow it to begin marketing generic Actos on Aug. 17, 2012...
Mylan, Takeda Bury Hatchet In Diabetes Drug Feud
To view the full article, take a free trial now.
